QL
VNDA icon

Quarry LP’s Vanda Pharmaceuticals VNDA Stock Holding History

Quarry LP’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,702
Closed -$53.4K – 2657
2025
Q3 		$53.4K Buy
+10,702
New +$49.5K 0.01% 804

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Quarry LP's VNDA Position: Q4 2025 in Review

Quarry LP sold out of Vanda Pharmaceuticals (VNDA) in Q4 2025, closing a stake of 10,702 shares — an estimated $53.4K sold.

Quarry LP first reported a position in VNDA in Q3 2025 and held it in 1 quarter. The position peaked at $53.4K in Q3 2025. 153 funds tracked by Wall St. Rank hold VNDA as of Q4 2025.

  • Quarry LP reported no remaining Vanda Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Quarry LP sold 10,702 Vanda Pharmaceuticals shares in Q4 2025, an estimated $53.4K.
  • Quarry LP first reported a position in Vanda Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Quarry LP's Vanda Pharmaceuticals position peaked at $53.4K in Q3 2025.
  • 153 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2025.

Based on Quarry LP's 13F filing for Q4 2025, filed 13 Feb 2026.